With sufficient evidence that the protein plays a substantial role in cancer progression, it may imply that MEK1 could be a potential target by the bioactive compounds of B. stenostachya. Likewise, MEK1 and CDK2 were found to be enriched in the PI3K-Akt signaling pathway. Here, MAP2K1 is linked to cancer.